BioSpace News Archive

Drug Development

Taiho Oncology and Servier Present LONSUR mCRC Data at ASCO 2018 Gastrointestinal Cancers Symposium

A phase I multicenter, open-label study examined the maximum tolerated dose of a LONSURF and oxaliplatin combination in patients with mCRC.

January 20, 2018
·
12 min read
Drug Development

Exelixis Announces Presentation of Updated Phase Ib Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib (COTELLIC), an Exelixis-discovered MEK inhibitor, in combination with atezolizumab (TECENTRIQ), an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer (CRC).

January 20, 2018
·
17 min read
Drug Development

Array BioPharma Release: Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer

The data were presented at the ASCO 2018 Gastrointestinal Cancers Symposium in San Francisco, California.

January 20, 2018
·
12 min read
Drug Development

Bristol-Myers Squibb Company Release: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer

With a median of 13.4 months of follow-up, the primary endpoint of objective response rate (ORR) per investigator assessment was 55% (95% CI: 45.2 to 63.8).

January 20, 2018
·
30 min read